查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703442

生物可吸收冠狀動脈支架市場－全球產業規模、佔有率、趨勢、機會和預測（按品牌、最終用戶、地區和競爭細分，2020-2030 年）

Bioresorbable Coronary Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Brand, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球生物可吸收冠狀動脈支架市場價值為 5.5009 億美元，預計在預測期內將大幅成長，到 2030 年的複合年成長率為 10.25%。心臟病學的最新進展顯著改善了冠狀動脈疾病 (CAD) 患者的治療效果和生活品質。在這些創新中，生物可吸收冠狀動脈支架已成為一種變革性的解決方案，標誌著 CAD 治療的典範轉移。與傳統的金屬支架不同，這些支架在發揮動脈支撐功能後會在體內逐漸溶解。

市場概覽
預測期 2026-2030
2024年市場規模 5.5009億美元
2030年市場規模 9.9008億美元
2025-2030 年複合年成長率 10.25%
成長最快的領域 醫院和診所
最大的市場 北美洲

市場促進因素

心血管疾病（CVD）盛行率不斷上升

市場挑戰

功效和安全問題

市場趨勢

技術進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：生物可吸收冠狀動脈支架市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按品牌（Magmaris、Magnitude、MeRes-100、DESolve、其他）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美生物可吸收冠狀動脈支架市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物可吸收冠狀動脈支架市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太生物可吸收冠狀動脈支架市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美洲生物可吸收冠狀動脈支架市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲生物可吸收冠狀動脈支架市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球生物可吸收冠狀動脈支架市場：SWOT 分析

第 14 章：競爭格局

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology (Beijing)Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16356

The Global Bioresorbable Coronary Stents Market was valued at USD 550.09 million in 2024 and is projected to witness substantial growth during the forecast period, registering a CAGR of 10.25% through 2030. Recent advancements in cardiology have significantly enhanced patient outcomes and quality of life for individuals suffering from coronary artery disease (CAD). Among these innovations, bioresorbable coronary stents have emerged as a transformative solution, marking a paradigm shift in CAD treatment. Unlike traditional metallic stents, these stents are designed to gradually dissolve within the body after fulfilling their function of arterial support.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 550.09 Million
Market Size 2030USD 990.08 Million
CAGR 2025-203010.25%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Market Drivers

Increasing Prevalence of Cardiovascular Diseases (CVDs)

The growing global incidence of cardiovascular diseases represents a key driver for market expansion. CVDs remain the leading cause of death globally, responsible for 17.9 million deaths in 2019-approximately 32% of global mortality. Notably, 85% of these fatalities were due to heart attacks and strokes. Furthermore, over 75% of CVD-related deaths occur in low- and middle-income countries, highlighting a critical gap in healthcare infrastructure and access to advanced cardiac care.

The rising number of patients diagnosed with coronary artery disease (CAD) has spurred demand for innovative treatment approaches like bioresorbable coronary stents. In 2022, the global prevalence of CAD was estimated at 315 million cases, with a 95% uncertainty range of 273 to 362 million. The age-standardized prevalence rate was recorded at 3,605 per 100,000 individuals, underscoring the widespread nature of the disease.

The aging global population is a significant contributing factor, as age is the most prominent non-modifiable risk factor for CAD and related cardiovascular conditions. According to the American Heart Association (AHA) 2019 update, 31% of men and 25.4% of women aged 80 and above are diagnosed with CAD. In addition, lifestyle factors such as hypertension, diabetes, obesity, and physical inactivity continue to escalate the global burden of cardiovascular risk, further supporting the shift toward bioresorbable stent adoption.

Market Challenges

Efficacy and Safety Concerns

Despite their promising potential, bioresorbable coronary stents face ongoing scrutiny regarding their clinical safety and efficacy. Some trials have raised concerns about the risk of stent thrombosis-the formation of blood clots within or near the stent-leading to potentially life-threatening complications. These concerns have prompted a comparative evaluation against conventional metallic stents, particularly in terms of long-term safety outcomes.

Market Trends

Technological Advancements

Rapid innovation in medical technology has significantly influenced the development and adoption of bioresorbable coronary stents. Continuous advancements in material science have enabled the creation of stents that maintain mechanical strength during initial healing phases while degrading safely thereafter. The use of biocompatible materials has improved both patient outcomes and procedural safety.

State-of-the-art manufacturing techniques such as 3D printing and laser cutting allow for the production of highly intricate stent designs, optimizing both radial strength and vascular conformability. Many stents are now developed with drug-eluting properties, enabling the controlled release of therapeutic agents to reduce risks of restenosis and inflammation.

Innovations in intravascular imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further enhanced procedural accuracy by providing high-resolution, real-time visualization of stent deployment. This precision supports optimal placement and expands the therapeutic potential of bioresorbable stents.

Ongoing clinical research and trials continue to refine stent designs and validate long-term outcomes, offering valuable data that guide next-generation product development and regulatory approvals.

Key Market Players

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology (Beijing)Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

Report Scope:

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioresorbable Coronary Stents Market, By Brand:

  • Magmaris
  • Magnitude
  • MeRes-100
  • DESolve
  • Others

Bioresorbable Coronary Stents Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Bioresorbable Coronary Stents Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Bioresorbable Coronary Stents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Bioresorbable Coronary Stents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Brand
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioresorbable Coronary Stents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Brand
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Bioresorbable Coronary Stents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Brand
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Bioresorbable Coronary Stents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Brand
        • 6.3.3.2.2. By End User

7. Europe Bioresorbable Coronary Stents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Brand
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bioresorbable Coronary Stents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Brand
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Bioresorbable Coronary Stents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Brand
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Bioresorbable Coronary Stents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Brand
        • 7.3.3.2.2. By End User
    • 7.3.4. France Bioresorbable Coronary Stents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Brand
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Bioresorbable Coronary Stents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Brand
        • 7.3.5.2.2. By End User

8. Asia-Pacific Bioresorbable Coronary Stents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Brand
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bioresorbable Coronary Stents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Brand
        • 8.3.1.2.2. By End User
    • 8.3.2. India Bioresorbable Coronary Stents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Brand
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Bioresorbable Coronary Stents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Brand
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Bioresorbable Coronary Stents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Brand
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Bioresorbable Coronary Stents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Brand
        • 8.3.5.2.2. By End User

9. South America Bioresorbable Coronary Stents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Brand
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bioresorbable Coronary Stents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Brand
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Bioresorbable Coronary Stents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Brand
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Bioresorbable Coronary Stents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Brand
        • 9.3.3.2.2. By End User

10. Middle East and Africa Bioresorbable Coronary Stents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Brand
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bioresorbable Coronary Stents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Brand
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Bioresorbable Coronary Stents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Brand
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Bioresorbable Coronary Stents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Brand
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Bioresorbable Coronary Stents Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. BIOTRONIK SE & Co. KG
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Meril Life Sciences Pvt. Ltd
  • 14.3. Elixir Medical Corporation.
  • 14.4. Reva Medical, LLC
  • 14.5. Terumo Corporation
  • 14.6. Lepu Medical Technology (Beijing)Co.,Ltd
  • 14.7. MicroPort Scientific Corporation
  • 14.8. LifeTech Scientific Corporation
  • 14.9. Boston Scientific Corporation
  • 14.10.Medtronic plc

15. Strategic Recommendations

16. About Us & Disclaimer